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ABSTRACT 
   Reteplase is a part of tissue plasminogen activator (t-PA) used for the removal of thrombi in blood vessels. In 
the present study we express the Reteplase gene in Escherichia coli TOP10 and then its thrombolytic activity was 
measured. The recombinant plasmid pBADgIIIA was transformed into the competent Escherichia coli TOP10 
and then transformed bacteria was seeded into bioreactor containing 1.5 L LB medium and induced by 0.02% L-
Arabinoseat 37°C, pH 7, and 180 rpm until OD 600 of 0.6 was reached. Samples were analyzed by SDS-PAGE 
and western blotting and the expression of Reteplase was examined. Finally the activity of this recombinant 
protein was evaluated using Chromogenic Activity Assay Kit. The presence of Reteplase in transformed 
Escherichia coli TOP10 was examined by western blotting which revealed that the target protein in form 
inclusion body was expressed as a unique band at 39 and the refolded Reteplase was 66 KDa. The amount of 
protein produced was 90.5 µg/mL and its activity was determined as 0.8 units. In this study, the expression of 
Reteplase in Escherichia coli TOP10 was scaled up under optimum condition. Furthermore we earned Reteplase 
with partially suitable thrombolytic activity. 
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INTRODUCTION 
    Tissue plasminogen activator (t-PA) is a protein 
involved in the breakdown of blood clots [1,2]. Each 
year, about 2 million patients through the world, are 
hospitalized because of acute myocardial infarction 
[3] and providing a suitable drug for the removal of 
thrombi is essential. t-PA is a selective thrombolytic 
agent that is a choice for the treatment of acute 
myocardial infarction [4]. t-PA converts 
plasminogen into plasmid to dissolve clot and 
restore blood flow. It also acts on other molecular 
targets, such as matrix metalloproteinase and low-
density lipoprotein receptor-related proteins that 
induce vascular remodeling, angiogenesis, 
neurogenesis and axonal regeneration [5]. The 
advantage of this protein is that this has no side 
effects such as systemic hemorrhage and fibrinogen 
depletion [4]. Reteplase is a recombinant non-
glycosylated form of human t-PA, which has been 
modified and contains 357 of the 527 amino acids of 
the original protein [6]. It is produced in the 
bacterium Escherichia coli. Reteplase is similar to 
the recombinant human t-PA (Alteplase), but the 
modifications in this protein, give reteplase a longer 
half-life of 13–16 minutes [7]. Reteplase also binds 
fibrin with lower affinity than Alteplase, and can 
penetrate into clots [7]. t-PA has five domains: F, 
EGF, P, Kringle 1 and Kringle 2 domains and the 
latter has 355 amino acids which is the active part of 
t-PA. Kringle 2 domain plus the first three amino 
acids of t-PA has been named reteplase which is 
available as a thrombolytic agent in the market [8]. 
E. coliis one of the most widely used prokaryotic 
hosts for the production of recombinant 
heterologous proteins and its genetic specifications 
are better characterized than those of any other 
microorganism [9]. The many advantages of E. 
colihave ensured that it remains a valuable organism 
for high-level production of recombinant proteins 
[10]. Reteplase can be targeted to the periplasmic 
space with less reducing environment compared to 
cytoplasm [11]. In this study, the pBAD/gIIIA 
vector that carries arapBAD promoter was used for 
the transformation of E. coliTOP10. Production of 
recombinant proteinis induced by adding L-
Arabinose to the medium.In this study, the 
expression of reteplase was performed in a stirred-
tank bioreactor at optimum conditions and its ability 
for converting the plasminogen to its active form 
(plasmin) was evaluated. 
 




MATERIAL AND METHODS 
Materials 
    Recombinant pET15b/reteplase was previously 
prepared at the School of Pharmacy of Isfahan 
University of Medical Sciences [12]. The 
pBAD/gIII plasmid and bacterial strain E.coli 
TOP10 were purchased from Pasteur Institute, Iran. 
Luria-Bertani (LB) media was prepared according 
to the guidelines in the laboratory manual offered by 
Sambrook and Russell [13]. Screening based on 
antibiotic resistance was performed on LB agar 
plates containing 100 µg/Ml ampicillin obtained 
from Sigma, Germany, and plasmid minipreparation 
kit was purchased from Fermentas Co., 
Poland.Finally, for comparing our recombinant 
Reteplase, the standard reteplase (Retelies
®
), was 
purchased from Osveh, Iran. 
Transformation of E. coli DH5αwith recombinant 
pET15b plasmids 
   Recombinant pET15b plasmid containing 
Reteplase gene were digested using NcoΙ and 
BamHΙ restriction enzymes to obtain Reteplase 
cDNA insert. pBADgIIIA vector, on the other hand, 
was digested with NcoΙ and BglΙΙ enzymes. Ligation 
process between vector and insert (molar ratio of 
3:1, vector to insert) was performedusing T4 DNA 
ligase for 30 minat room temperature. This 
recombinant pBADgIIIA vector was transformed to 
E. coli TOP10 using heat shock method (42°C, 1.5 
min), spread on LB agar plates containing 100 
µg/ml ampicillin and incubated overnight at 37°C. 
Finally, the obtained recombinant pBAD/gIIIA 
plasmids containing reteplase gene were sequenced 
(Gene Fanavaran, Iran) using the Analyzer Genetic 
Device and Capillary Base.  
Expression of Reteplase in stirred-tank bioreactor 
    One colony of E. coli TOP10 containing 
recombinant plasmid was cultured in 5 ml LB 
medium (1% tryptone, 0.5% yeast extract, and 1% 
NaCl) at 37°C and 180 rpm overnight. This culture 
was inoculated into 150 mlof LB medium 
containing ampicillin (100 µM) and finally the 
culture was inoculated into 1500 ml of LB medium 
supplemented with ampicillin and was injected to 
stirred-tank bioreactor (BioTron, Korea) at37°C, pH 
7, and 180 rpm until OD600 nm of 0.4-0.6 was 
reached. L-Arabinose was then added (final 
concentration: 0.02%). Thefinal OD600 of inoculum 
was readand the samples were centrifuged at 7000 
×g, 4°Cfor 15 minand the final product was stored at 
-20°C [14,15]. 
Preparation, solubilization and refolding of 
inclusion bodies  
    All pellets were resuspended in 150 ml of buffer 
containing 0.1 M Tris and 20 mM EDTA and 
homogenized using a shearing rod, Micro Smash 
(Tomy, Japan).Lysozyme 0.25 mg/ml was then 
added to the samplesand incubated for 30 minon ice. 
Subsequently, centrifugation was carried out for 30 
min at 4°C (13000 ×g). The pellets were 
resuspended in 90 ml buffer containing 0.1 M Tris, 
20 mM EDTA and 2.5% V/V Triton X-100 and 
homogenized again. Then the samples were 
centrifuged, and resuspended in 90 ml of 0.1M Tris, 
20 mM EDTA and 0.5% v/vTriton X-100 solution 
and homogenized. The samples were 
thencentrifuged for 30 minat 4°C and 13000×g and 
the pellets were resuspendedin 75 ml of 0.1 M of 
Tris and 20 mM EDTA [16, 17]. The prepared 
inclusion bodies were stored at -20°C. 
After preparation the inclusion bodies, proteins were 
extracted by resuspension in Tris 25 mM, EDTA 10 
mM, containing 1% Triton X-100 and urea 8M [18]. 
The reducing agent and buffer components were 
separated by dialysis (pH=7) at 4°C [19,20]. The 
solubilized samples were incubated in a mixture of 
Tris 0.1 mol/L (pH=8.5), urea 8mol/L, EDTA 2 
mmol/L, and 2-mercaptoethanol 1%. Subsequently, 
the pH of the solution was adjusted to 7 with 
concentrated hydrochloric acid (12 N). Refolding of 
the protein took place by dilution with 0.1 mol/LTris 
(pH=10.5), 0.5 M L-argenine, 1 mM EDTA, 6 M  
urea, 1mM reduced glutathione, 0.1 mM oxidized 
glutathione, and 1 mg/ml bovine serum albumin. 
Then, the samples were incubated for 24 hours at 
20°C in 180 rpm [19,20]. 
Dialysis of refolded proteins 
    The reducing agent and buffer components were 
separated by dialysis of the protein samples using 
0.1 M Tris and 1mM  EDTA (pH=8) buffer, and this 
stage was repeated three times for 1 hour and final 
repeat was performed for 24 hours [19,20].  
SDS-PAGE analysis  
    One sample of inclusion bodies was dissolved in 
PBS buffer (pH=7.4). The refolded proteins were 
also prepared and Retelies
®
 dissolved in PBS buffer 
too. subsequently all samples were boiled for 5 min 
at 85°C and electrophoresed on a 12% (v/v) non-
continues SDS-PAGE with 5% stacking gel. 
 




Subsequently, the gels were stained with Coomassie 
blue G250. 
Western blot analysis  
     The protein samples on the SDS-PAGE were 
transferred onto an immobilon-P 
polyvinylidenediflouride membrane, 0.45 micron 
pore size, 10 ×10 (Sigma, Germany). For 
preparation of the membrane, it was put on 
methanol for 15 sec and then transferred to TB 
(transfer buffer) for additional 3 min. transferringof 
proteins onto this membrane was performed for 
1hour with 400 mA of electric current. After 
incubation of the blot with blocking buffer (5% non-
fat dry milk in TB) overnight at 4°C, anti His-tag 
antibody (anti t-PA, 1:250 to 1:1000 in TB-Tween 
buffer) was added and incubated for 1 hour at room 
temperature. Subsequently, three washes with TB-
Tween buffer were performed and anti-rabbit IgG-
HRP conjugate (Roche, Germany) as secondary 
antibody (diluted 1:5000) was added (incubated at 
room temperature for 1 hour). The membrane was 
washed three times with 10 mlTB-Tween for 10 
min. The TB-Tween solution was then removed, 
and for detection of bands, 9 mg of 3,3-
Diaminobenzidine (DAB, Sigma, Germany) was 
used and after dissolution, H2O2 30% was added. 
The bands were detected after 24 hours. 
Measurement of Reteplase activity  
    Activating of plasminogen by reteplase was 
detected by Chromogenic Activity Assay Kit. Assay 
diluent (50 µL), plasminogen (10 µL) and plasmin 
substrate (20 µL) was added to 20 µL of tPA 
standard Reteplase (Retelies
®
) as positive control for 
total volume of120 µL. This stage was repeated for 
20 µL of the samples and 20 µL of water as blank 
and these materials were added to the supplied 96-
well plate. The plate was incubated at 37°Cin a 
humid incubator and the absorbance at 405 nmwas 
measuredafter 1 hour for each sample. 
 
RESULTS 
Cloning of Reteplase 
     Digestion of recombinant pBADgІІIA plasmid 
containing Reteplase with NcoІ and HindIII created 
a band in about 4145 bp which is equal to the 
molecular size of pBADgІІIA and another in 




Figure 1. Digestion of the recombinant pBAD/gІІI plasmid 
with EcoRI, NcoІ and HindІІІ. Lane 1: Standard molecular 
weight marker. Lane 2: Obtained vector (4145 bp) after 
digestion with EcoRI, Lane 3 Obtained insert (1128 bp) and 
vector (4145 bp) after digestion with the above mentioned 
enzymes.  
 
Figure 2. SDS-PAGE of the periplasmic and inclusion 
bodies proteins. Lane 1: Standard marker. Lane 2: Inclusion 
body from uninduced cells containing recombinant 
pBAD/gІІІ. Lane 3: inclusion body from cells induced 
induced with 0.02% L-Arabinose (2 hrs). Lane 4: periplasmic 
protein from induced sample with 0.02% L-Arabinose (2 hrs) 
Lane 5: periplasmic protein from uninduced sample. 
 





Figure 3. SDS-PAGE of the proteins extracted from inclusion bodies before and after refolding. Lane 1: Standard molecular weight 
marker. Lane 2: inclusion body of recombinant pBAD/gІІІ plasmids containing Reteplase. Lanes 3 and 4: Obtained proteins after 
refolding .and Lane 5, 6: commercially available Reteplase. 
 
 
Figure 4. Western blot analysis by DAB staining method. 
Lane 1: Standard molecular weight marker, Lane 2: inclusion 
body of recombinant Reteplase (39 KDa), Lane 3: refolded 
recombinant Reteplase (66 KDa). 
 
Furthermore digestion of this recombinant vector 
with EcoR1 created a band at about 478bp (Figure 
1) and this confirm the existence of insert in 
vector. Sequencing of this plasmid also confirmed 
the presence and correct orientation of Reteplase 
cDNA in the pBADgІІIA plasmid. 
 
Expression of Reteplase in bioreactor 
    After the transformation of pBADgІІIA 
plasmid containing Reteplase gene to E. coli 
TOP10, the effect of theconcentrationof L-
Arabinose (0.02%) onprotein expression was 
evaluated for2 hoursincubation time at 37°C. The 
final OD600 was determined as 1.3. The 
expressed proteins were electrophoresed using 
SDS-PAGE. A protein with an estimated size of 
∼39 KDa was observed in SDS-PAGE for 
samples as inclusion body (Figure 2). After 
solubilization of inclusion bodies, refolding and 
dialysis of reteplase, it was analyzed using SDS-
PAGE and compared with the Retelies
® 
which 
showed bands at ∼66 and 39KDa, respectively 
(Figure 3). 
Western blotting  
     The obtained Reteplase was confirmed by 
Western Blotting (Figure 4). 
Activity of Reteplase 
     The activity of the obtained recombinant 
protein was analyzed using standard t-PA enzyme 
activity kit and commercially available Reteplase 
(Retelies
®
). The differences in the absorbance 
(405 nm) in the reaction solution was directly 
attributedto the t-PA enzymatic activity.  
 




The concentrations of t-PA standard kit and 
Retelies
® 
with 1 U/mL activity were both 20.6 
µg/mL. The enzymatic activity of samples 
wasmeasured as 0.8 U/mL compared to Retelies
®
. 
The concentration of samples determined using 
Bradford test according to the standard curve of 
BSA (albumin serum), was 90.5 µg/mL. 
 
DISCUSSION 
     Reteplase is a potential recombinant 
thrombolytic drug that may offer an appropriate 
alternative to currently employed plasminogen 
activators. Furthermore, this agent appears to be 
an acceptable alternative thrombolytic agent with 
a satisfactory safety and efficacy profile in the 
setting of peripheral arterial and venous 
occlusion. Reteplase may provide an attractive 
alternative for the treatment of peripheral arterial 
and venous thrombotic occlusions [21].Therefore, 
the present research was conducted to produce 
recombinant reteplase in E. coli TOP10in large 
scalesusing astirred-tank bioreactor. Previously, 
the recombinant Reteplase was produced in 
Pichia Pastoris in shaking flask and optimized 
[22]; however, because the Reteplase is a non-
glycosilated protein, it is not necessary to produce 
in eukaryotic systems and using of a prokaryotic 
host is simpler and cheaper for production of such 
recombinant proteins. The usage of pBADgІІI 
vector for producing recombinant proteins has 
been reported by many investigators 
[10,19,18,23], although none of them have 
studied the expression of reteplase in this system. 
In order to cloning this insert, we used NcoΙ and 
BamHΙ restriction enzymes to obtain Reteplase 
cDNA insert and NcoΙ and BglΙΙ for digesting 
pBADgIIIA vector. Although BamHΙ and BglII 
have different restriction sites but after the 
digestion, the sticky ends created by two these 
enzymes can to adhere and create a recombinant 
vector containing insert. pBADgІІI vector adds a 
signal sequence at the N-terminal of reteplase 
gene, enabling it to be secreted into the 
periplasmic space, and this provides a better 
environment for proper folding of the enzyme and 
formation the disulfide bond become easier [23]. 
Furthermore the effect of host destructive 
protease on the protein is decreased [23]. This 
vector also adds a 6× His amino acids (His-tag) in 
C-terminal of our protein that facilitates the 
purification of Reteplase by nickel-affinity 
chromatography. In this study, the amount of the 
expressed protein in periplasmic space was low 
and most ofit was present inside the cell as 
inclusion bodies. This might be due to high 
expression of proteins disturbing the mechanisms 
of cells for exporting recombinant proteins to the 
periplasmic space. Similar results have been 
reported by other investigators [12,15]. The main 
advantage of inclusion bodies is that they are 
mostly composed of recombinant proteins (25% 
of total protein), can be easily isolated from the 
cell debris, furthermore this form of protein is 
inactive and thus it can be produced in large 
amounts for cell toxic protein and finally, the 
inclusion bodies are resistant to the host protease 
and don’t require to protease free hosts [2,14,24]. 
However, inclusion body form of proteinsis 
insoluble and inactive [9,12,13,24,25]. Thus, the 
main problem in purification process of inclusion 
bodies is optimizing the refolding and 
renaturation conditions by preventing the 
formation of inactive aggregates. 
Differentrefolding strategies have been used for 
refolding the protein and in this study we used 
arginine and oxidizing/reducing glutathione [26]. 
There are several reports about the use of 
oxidizing/reducing glutathione in refolding of 
recombinant proteins such as prochymosin, 
growth hormone and alkaline phosphatase [27]. 
The process of refolding reteplase may result in 
the dimerization of the protein or change of its 
disulfide bandsso that it’s molecular weightshows 
higher in the SDS-PAGE although it is active. 
According to the SDS-PAGE analyze, the 
molecular weight of the Retelies
®
 is 39 KDa and 
this form has more activity than our product. 
Therefore, it seems that changing refolding 
protocol is necessary.   
Theactivity of our product is lower than the 
positive control and this may be due tothe 
presence of His-tag in the sequence of the gene 
that facilitates the purification of reteplase using 
affinity chromatography with nickel in stationary 
phase. But decrease the thrombolytic activity of 
this protein. 
Qiu et al and Lee and Im, have also produced 
tissue plasminogen activators and measured their 
activities [2,28]. However, the unit activity of 
reteplase is defined differently as compared to 
 




other types of t-PA and therefore the results of these 
investigations cannot be compared with our study. 
In this study, we controlled key parameterssuch as 
rpm, temperature, pH, and foam formation.Because 
of the lack of floor during the process, anti-foaming 
agent was not used.pHdid not change significantly 
during the growth of the bacteria and therefore acid 
or base was not added. An important aspect of our 
study is large-scale production of reteplase in a 
bioreactor, since no other study has been published 
for mass production of this drug.  
On the other hand, it seems that production of a 




     In this study, the expression of reteplase in 
Escherichia coli TOP10 was performed in 
optimum conditions and scaled up. 
In future studies, purification and removing the 
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